Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC

Titre traduit de la contribution: Immunothérapie des tumeurs de la vessie n'infiltrant pas le muscle: immunothérapies et TVNIM

Yohann Loriot, Morgan Rouprêt

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    2 Citations (Scopus)

    Résumé

    Local and systemic immunotherapies are used for the management of bladder cancer in daily practice. BCG has been administered for almost 40 years in patients with non-muscle invasive bladder cancer (NMIBC). Despite its efficacy, disease progression is observed in nearly 30% of patients. Given the antitumor activity of immune checkpoint inhibitors in metastatic setting, these therapies are currently investigated in NMIBC. Pembrolizumab is now approved by the Food and Drug Administration (FDA) for the treatment of patients with BCG-unresponsive, high-risk, NMIBC with carcinoma in situ with or without papillary tumors who are ineligible for or have not elected to undergo cystectomy. Several phase 3 trials are ongoing to investigate the efficacy of PD(L)1 inhibitors combined with BCG such as ALBAN study in France.

    Titre traduit de la contributionImmunothérapie des tumeurs de la vessie n'infiltrant pas le muscle: immunothérapies et TVNIM
    langue originaleAnglais
    Pages (de - à)S49-S55
    journalBulletin du Cancer
    Volume107
    Numéro de publication5
    Les DOIs
    étatPublié - 1 juin 2020

    Contient cette citation